M
yosin binding protein C (MyBP-C) is a substantial component of the striated muscles located in the C zone of the A band of the thick filament of the sarcomere. Three isoforms have been identified in adult striated muscle: a fast skeletal, a slow skeletal, and a cardiac isoform.
1,2 For a decade, several lines of evidence have pointed to a potentially important structural and regulatory role of MyBP-C in the sarcomere. MyBP-C participates in the assembly of the thick filaments in striated muscle through several protein-protein interactions: it is intimately associated with myosin subfragment-2 and light meromyosin 3 ; it competes with myosin subfragment-1 for binding to F-actin, which results in a modulation of the myosin ATPase activity 4, 5 ; and last, it binds to titin (or connectin). 6, 7 The addition of MyBP-C modulates the actin-activated ATPase activity of skeletal and cardiac myosins 5, 8, 9 ; conversely, partial extraction of MyBP-C from rat skinned cardiac myocytes and rabbit skeletal muscle fibers alters Ca 2ϩ -sensitive tension. 10 Cardiac MyBP-C is phosphorylated under adrenergic stimulation, [11] [12] [13] and it was recently shown that this phosphorylation alters myosin crossbridges in native thick filaments isolated from rat ventricles, suggesting that MyBP-C can modify force production in activated cardiac muscles.
14 Finally, several mutations in the gene encoding the cardiac isoform in humans (MYBPC3) have been identified in unrelated families with FHC. [15] [16] [17] FHC is an autosomal-dominant disease characterized by a ventricular hypertrophy predominantly affecting the interventricular septum and associated with a large extent of myocardial and myofibrillar disarray. It is the most common cause of sudden death in young athletes. Many forms of the disease involve mutations in genes encoding sarcomeric proteins (for reviews, see References 18 to 20) , and the finding that MYBPC3 is one of these disease genes markedly strengthens the hypothesis that cardiac MyBP-C plays an important role in the regulation of cardiac contraction in health and disease. Major insights into the functional consequences of the mutations and the pathogenesis of FHC were obtained through analysis of skeletal muscle biopsies of FHC patients with mutations in the ␤-MHC gene. 21, 22 This approach could be achieved because the ␤-MHC gene is normally expressed in both cardiac and slow-twitch adult skeletal muscles (see Reference 23 for a review). This is not the case for the cardiac MyBP-C gene: it is not expressed in adult skeletal muscles, and human cardiac biopsies are seldom available. In chickens, it was shown that cardiac MyBP-C is transiently expressed in embryonic skeletal muscles. 24 -26 We have investigated by in situ hybridization the pattern of expression of the cardiac MyBP-C gene during human development with the idea that if this gene is transiently expressed in embryonic and/or fetal skeletal muscles, satellite cells from adult skeletal muscles could be used as a model system to analyze in vitro the transcription, the translation, and the function of cardiac MyBP-C. The expression of the titin gene was used as a control of skeletal muscle development. Furthermore, with a view to the development of animal models for FHC, we have also analyzed the pattern of expression of the cardiac MyBP-C gene in mice.
Materials and Methods

Human Tissues
Normal human embryos (from 4 to 7 postovulatory weeks) were obtained from legal abortions induced by mifepristone (RU486) at the Broussais Hospital in Paris. All procedures were approved by the Ethical Committee of the Necker-Enfants Malades Hospital in Paris. Each sample was first observed macroscopically during dissection under a stereomicroscope; the developmental stage of the embryo was determined using established criteria. 27 The heads and spinal cords of the 10-to 12-week-old fetuses were not available for analysis. Fetal human hearts at 15, 17, and 21 weeks of development were also included in this study.
Murine Tissues
Murine embryos of the NMRI strain, from 9.5 days post coitum to birth were examined. Tissues were collected shortly after delivery and frozen within the first 24 hours post mortem in dry ice and stored at Ϫ80°C until used. Ten-micron-thick cryostat sections were mounted on slides previously coated with a 2% 3-aminopropyltriethoxysilane solution in acetone. The sections were postfixed for 20 minutes in 2% paraformaldehyde in a 0.1 mol/L phosphate buffer (pH 7.4) at room temperature, rinsed (once for 2 minutes) in a phosphate buffer, rinsed briefly in water, and dehydrated with a series of washes in ethanol solutions (50%, 75%, and 100%). The sections were then air-dried and finally stored at Ϫ80°C. The integrity of each embryo was checked using conventional histological and histochemical staining techniques.
Oligonucleotide Probes
Purified 60mer oligonucleotide antisense cardiac MyBP-C cDNA probes were determined according to either the human sequence (EMBL accession number X84075), 5Ј-AAC ACG GCA GGG CTG CCT GCG GCC ACT TCC ACT GAC CGT GGC TTC TTG CTA AAG GCT GAG-3Ј, or the murine sequence, 28 5Ј-ACA CGG CAG CAC TGC CAG CAG TCA CCT CCG CTG ACC TTG GCT TCT TGT TGA AGG CTG ACA-3Ј. These probes were chosen in the 5Ј cDNA sequence in order to recognize only the cardiac variant. The probe specific to the titin gene was chosen in the A-band sequence in order to recognize both the cardiac and skeletal isoforms as described by Fougerousse et al. 29 Control sense probes were chosen from the opposite cDNA strands.
Northern Blot Analysis
All oligonucleotide probes (100 ng) were 5Ј end-labeled with [␥-32 P]ATP (New England Nuclear) using T4 polynucleotide kinase (Promeg) for 1.5 hours at 37°C and then separated from the free nucleotides by chromatography on Biospin 6 columns (Bio-Rad).
Mouse and human multiple-tissue Northern blots (Clontech) were prehybridized for 30 minutes at 65°C with ExpressHyb hybridization solution (Clontech). Hybridizations were performed at 65°C for 1.5 hours with the corresponding probes (1ϫ10 6 cpm/mL). The blots were washed for 20 minutes in 2ϫ SSC and 0.1% SDS at room temperature and for 20 minutes in 0.1ϫ SSC and 0.1% SDS at 37°C. The blots were then exposed to X-Omat film (Kodak) at Ϫ80°C for several hours.
In Situ Hybridization
All probes were 3Ј end-labeled with [␣-
35 S]dATP (Dupont-Nemours) using terminal deoxyribonucleotidyl transferase (BRL) and purified on Biospin columns (Bio-Rad). The in situ hybridization medium contained 50% formamide, 4ϫ SSC, 1ϫ Denhardt's solution, 0.25 mg/mL sheared salmon sperm DNA, 0.25 mg/mL polyA, 0.25 mg/mL tRNA, 10% dextran sulfate, 100 mmol/L DTT, and [␣-
35 S]dATP-labeled probe (6ϫ10 6 cpm/mL). One hundred microliters of the hybridization solution was deposited on each section, which was then covered with a parafilm coverslip and incubated in a humidified chamber at 43°C for 20 hours. After hybridization, the sections were washed, twice for 15 minutes each at 55°C in 1ϫ SSC containing 10 mmol/L DTT, twice in 0.5ϫ SSC containing 10 mmol/L DTT, and finally in 0.5ϫ SSC containing 10 mmol/L DTT at room temperature. The sections were then dehydrated with a series of graded concentrations of ethanol, exposed to Amersham Betamax x-ray films for 12 days, and then dipped in Kodak NTB-2 nuclear track emulsion and exposed for 2 months before development. The sections were examined using a Zeiss Axiophot microscope. Negative controls of in situ hybridization were tested with the sense probes on adjacent slides.
Results
Northern blot analysis of polyA ϩ RNA isolated from several adult murine and human adult tissues with the cardiac-specific MyBP-C oligonucleotide probes showed that an mRNA of Ϸ4.5 kb was detected abundantly in cardiac muscle, although it was absent in skeletal muscle, brain, spleen, lung, liver, kidney, and testis in both humans and mice (data not shown). The size and tissue specificity of this mRNA are in full agreement with previous cloning data, 11, 28 and this clearly shows that the chosen oligonucleotide probes are specific to the cardiac MyBP-C isoform in both animal species.
At 4 weeks of human development (Fig 1A through 1D) , a strong labeling of cardiac MyBP-C mRNAs was unambiguously detected in the whole embryonic heart (Fig 1B) . No signal could be detected in the myotome compartment ( Fig  1B) . No signal was detected with the human control sense probe (Fig 1D) . In contrast, titin mRNAs were clearly present both in the heart and in the myotome compartment (Fig 1C) . In 10-to 12-week-old fetuses (Fig 1E through 1G) , cardiac MyBP-C mRNAs were detected throughout the four-chambered heart (Fig 1F) . At this stage, cardiac MyBP-C mRNAs were not expressed in fetal skeletal muscles, whereas titin mRNAs were detected at significant levels (Fig 1G) . Transcription of the cardiac MyBP-C gene persisted uniformly in the later hearts studied but was not present in skeletal muscles (15, 17 , and 21 weeks old) (data not shown).
Sagittal sections of murine embryos were investigated systematically with the cardiac MyBP-C oligonucleotide probe from E 9.5 to E 18.5 (Fig 2) . At E 9.5, the primitive heart tube was strongly and specifically labeled (Fig 2D) . No signal was detected with the murine control sense probe (Fig 2E) . This cardiac-specific pattern of hybridization was also seen at E 10.5
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DTT ϭ dithiothreitol E (with number) ϭ embryonic day FHC ϭ familial hypertrophic cardiomyopathy MHC ϭ myosin heavy chain MyBP-C ϭ myosin binding protein C and E 18.5 (Fig 2F and 2G) , without any expression of the cardiac MyBP-C gene in skeletal muscle territories.
Discussion
The present study is the first analysis of the expression pattern of the cardiac MyBP-C gene during human and murine development. We show that the message for cardiac MyBP-C is detected in the ventricles and atria at very early stages in both human and mouse development, but we did not find any expression of the cardiac MyBP-C gene during skeletal muscle development. Furthermore, using reverse-transcriptase polymerase chain reaction, we were unable to detect cardiac MyBP-C transcripts during the differentiation of C2-C12 skeletal muscle cells in culture, hence confirming that there is no expression of cardiac MyBP-C gene in skeletal muscle (data not shown). This result is at variance with what has been described in the chicken: it was found that cardiac MyBP-C is expressed in both cardiac and skeletal muscle during embryonic development. 24 -26 This probably reflects a difference in the organization of the promoter region of the avian and the mammalian genes. After the embryonic stages in chicken skeletal muscles, cardiac MyBP-C is replaced subsequently by both slow skeletal and fast skeletal isoforms in late embryonic development, after which the slow skeletal isoform disappears and only the fast skeletal isoform persists during postnatal development. Two splice variants of the cardiac MyBP-C gene were found in chicken development, and further investigations will be required to determine whether splice variants also exist in mammals. Nevertheless, it is reasonable to assume that even if several variants are transcribed from the human and murine cardiac genes, they would follow the same pattern of expression.
The appearance of the sarcomeric protein gene transcripts that interact directly or indirectly with MyBP-C in the newly formed cardiac tube is very similar to that reported in the present study for cardiac MyBP-C. In humans, the ␤-MHC, cardiac ␣-actin, and titin genes are expressed at a high level in the embryonic heart from Ϸ4 weeks of development (the present study, Reference 30, and, for a review, Reference 23). In the mouse embryo, mRNAs encoding ␤-MHC, titin, and cardiac ␣-actin are all detected at high levels at 8 days post coitum (for review, see Reference 31) . One might thus hypothesize that the potential impairment of sarcomerization associated with FHC occurs very early during development for the two major causative genes, ␤-MHC and cardiac MyBP-C. In this context, mice expressing the ␤-MHC mutant are good models for FHC. 32, 33 Since the cardiac MyBP-C gene is expressed uniquely in the heart, it is clear that analyses of the consequences of the mutations at molecular and cellular levels will not be possible in human skeletal muscle biopsies and that animal models will be needed. Our present results suggest that the expression of cardiac MyBP-C mutants in mice should also resemble the expression in human disease and will help to resolve the pathogenesis of FHC. , and E 18.5 (C and G). A, B, and C, Phase-contrast microscopy at E 9.5, E 10.5, and E 18.5, respectively. D, F, and G, Dark-field microscopy, in situ hybridization with the cardiac MyBP-C antisense probe. E, Dark-field microscopy, in situ hybridization with the cardiac MyBP-C sense probe. H indicates outflow tract of heart; V, ventricular chamber of heart; TA, truncus arteriosus; RA, right atrium of heart; LV, left ventricle of heart; AO, aorta; S, somite; F, forebrain; NT, neural tube; SP, spinal cord; T, tongue; DI, diaphragm; O, oropharynx; and G, gut. Barsϭ600 m (A) and 5 mm (B and C). Panels D and E are photomicrographs, and panels F and G are autoradiographic reproductions.
